The ‘Godzilla’ of Weight Loss Drugs Could Take ‘Ozempic Face’ to the Extreme

Résumé détaillé
“Reta face is the new Ozempic face,” dermatologist Gary Goldenberg declared to Men’s Health. “Since retatrutide is a triple biologic agonist that produces more significant weight…
From sunken under-eyes to hollow temples and loose skin, many people using weight-loss drugs report dramatic side effects on their appearance. Now, experts say an upcoming weight-loss drug could make these unwanted facial changes even more striking.
Eli Lilly, the company behind weight-loss medication Zepbound and type 2 diabetes medication Mounjaro, is reportedly developing a new drug already dubbed the “Godzilla” of weight-loss drugs.
Drugs like Ozempic and Wegovy are glucagon-like peptide-1 (GLP-1) receptor agonists, while Mounjaro and Zepbound are dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
But retatrutide, usually referred to online as reta or retta, activates three receptors: GLP-1, GIP, and glucagon. Initial results show the drug could more than double the weight loss patients experience on Ozempic.
The U.S. Food and Drug Administration has not yet reviewed retatrutide, but Eli Lilly plans to apply in early 2027.
Some people, however, are already purchasing reta, or drugs that claim to be reta, through the gray market, and posting their weight loss transformations online. But beyond their bodies, the weight loss is also affecting their faces.
“Reta face is the new Ozempic face,” dermatologist Gary Goldenberg declared to Men’s Health. “Since retatrutide is a triple biologic agonist that produces more significant weight loss than GLP peptides, patients may have an even more exaggerated appearance of a sunken, aged look.”
He added, “Facial bones can also become more prominent as fat disappears. The skin can thin, as collagen and elastic fibers have less underlying fat plumping them up.”
Traditionally, weight loss happens gradually over time. But with GLP-1-assisted weight loss, transformations can be considerably faster, leaving the skin less time to adjust.
Début de l'article, extrait de Daily Beast. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.thedailybeast.com)



